DLHC vs. MXCT, BWMN, GRVY, SOHU, ABSI, OOMA, IBEX, EGHT, PMTS, and RGP
Should you be buying DLH stock or one of its competitors? The main competitors of DLH include MaxCyte (MXCT), Bowman Consulting Group (BWMN), Gravity (GRVY), Sohu.com (SOHU), Absci (ABSI), Ooma (OOMA), IBEX (IBEX), 8X8 (EGHT), CPI Card Group (PMTS), and Resources Connection (RGP). These companies are all part of the "business services" industry.
DLH vs.
MaxCyte (NASDAQ:MXCT) and DLH (NASDAQ:DLHC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings, analyst recommendations and community ranking.
DLH has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than DLH, indicating that it is currently the more affordable of the two stocks.
DLH has a net margin of 1.87% compared to MaxCyte's net margin of -78.36%. DLH's return on equity of 6.88% beat MaxCyte's return on equity.
68.8% of MaxCyte shares are held by institutional investors. Comparatively, 67.3% of DLH shares are held by institutional investors. 3.0% of MaxCyte shares are held by insiders. Comparatively, 21.6% of DLH shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
MaxCyte currently has a consensus price target of $9.50, suggesting a potential upside of 115.91%. Given MaxCyte's stronger consensus rating and higher probable upside, analysts clearly believe MaxCyte is more favorable than DLH.
MaxCyte has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Comparatively, DLH has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500.
In the previous week, DLH had 1 more articles in the media than MaxCyte. MarketBeat recorded 7 mentions for DLH and 6 mentions for MaxCyte. MaxCyte's average media sentiment score of 1.89 beat DLH's score of 0.94 indicating that MaxCyte is being referred to more favorably in the media.
DLH received 279 more outperform votes than MaxCyte when rated by MarketBeat users. However, 84.62% of users gave MaxCyte an outperform vote while only 65.17% of users gave DLH an outperform vote.
Summary
DLH beats MaxCyte on 10 of the 18 factors compared between the two stocks.
Get DLH News Delivered to You Automatically
Sign up to receive the latest news and ratings for DLHC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (NASDAQ:DLHC) was last updated on 1/13/2025 by MarketBeat.com Staff
